{"protocolSection":{"identificationModule":{"nctId":"NCT02245087","orgStudyIdInfo":{"id":"ECAD001"},"organization":{"fullName":"University Health Network, Toronto","class":"OTHER"},"briefTitle":"Eliminate Coronary Artery Disease","officialTitle":"Eliminate Coronary Artery Disease","acronym":"ECAD"},"statusModule":{"statusVerifiedDate":"2022-05","overallStatus":"TERMINATED","whyStopped":"Lack of Funding","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-09","type":"ACTUAL"},"completionDateStruct":{"date":"2019-09","type":"ACTUAL"},"studyFirstSubmitDate":"2014-09-11","studyFirstSubmitQcDate":"2014-09-17","studyFirstPostDateStruct":{"date":"2014-09-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-05-27","lastUpdatePostDateStruct":{"date":"2022-06-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Michael Farkouh","investigatorTitle":"Chair of the Peter Munk Centre of Excellence in Multinational Clinical Trials, Peter Munk Cardiac Centre, UHN","investigatorAffiliation":"University Health Network, Toronto"},"leadSponsor":{"name":"University Health Network, Toronto","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization."},"conditionsModule":{"conditions":["Coronary Artery Disease"],"keywords":["atorvastatin","coronary artery disease","myocardial infarction","stroke","revascularization"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atorvastatin","type":"EXPERIMENTAL","description":"Atorvastatin(Lipitor) in addition to the usual guideline based care","interventionNames":["Drug: Atorvastatin"]},{"label":"Guideline based care","type":"NO_INTERVENTION","description":"Current guidelines for lipid-management in healthy middle aged men and women only."}],"interventions":[{"type":"DRUG","name":"Atorvastatin","description":"20 mg of atorvastatin daily","armGroupLabels":["Atorvastatin"],"otherNames":["Lipitor"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period","timeFrame":"Up to 10 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men 35-50 years of age\n* Women 45 - 59 years of age (must be sterile or \\>2 years postmenopausal)\n* LDL cholesterol greater than 1.8 mmol/L (70 mg/dL) based on testing performed within 1 year\n* One risk factor for Coronary Heart Disease other than lipid abnormality:\n* Obesity and hypertension \\[BP \\>140 mmHg systolic and waist circumference \\> 100 cm in men and \\>90 cm in women\\]\n* family history of premature myocardial infarction \\[\\<60 years\\]\n* South Asian ethnic history\n* currently smoking\n\nExclusion Criteria:\n\n* Currently taking cholesterol lowering medication\n* Qualify for cholesterol lowering medication based on current guidelines\n* Significant renal dysfunction (creatinine clearance \\<30 ml/min)\n* Significant hepatic dysfunction (AST/ALT \\>2.0 times upper limit of normal)\n* Active malignancy\n* Diabetes\n* Progressive or terminal illness, or other condition in which subject is unlikely to survive the study period\n* Known allergy, hypersensitivity (anaphylaxis) ar adverse reaction to any statin\n* Participation in a clinical trial (except observational studies) within previous 30 days\n* Received any investigation product within 30 days prior to participation in this clinical trial\n* Previously enrolled in this clinical trial","healthyVolunteers":true,"sex":"ALL","minimumAge":"35 Years","maximumAge":"59 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dr Michael Farkouh, MD, FRCPC, MSc, FACC","affiliation":"Peter Munk Cardiac Centre, University Health Network","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Michael J Domanski, MD","affiliation":"University of Maryland Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Dr. Killian De Blacam Family Medical Practice","city":"Sudbury","state":"Ontario","zip":"P3A 2A3","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"Dr. Gregory Garrioch Family Medical Practice","city":"Sudbury","state":"Ontario","zip":"P3E 3C6","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"Dr. Reena Dhatt","city":"Sudbury","state":"Ontario","zip":"P3E6C3","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}}]},"referencesModule":{"references":[{"pmid":"26483108","type":"DERIVED","citation":"Domanski MJ, Fuster V, Diaz-Mitoma F, Grundy S, Lloyd-Jones D, Mamdani M, Roberts R, Thorpe K, Hall J, Udell JA, Farkouh ME. Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial. J Am Coll Cardiol. 2015 Oct 20;66(16):1828-1836. doi: 10.1016/j.jacc.2015.08.857."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003324","term":"Coronary Artery Disease"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000003327","term":"Coronary Disease"}],"ancestors":[{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Coronary Artery Disease","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","asFound":"Coronary Artery Disease","relevance":"HIGH"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Coronary Artery Disease","relevance":"HIGH"},{"id":"M11845","name":"Myocardial Infarction","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069059","term":"Atorvastatin"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","asFound":"Functional","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}